Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.96
(30.67%)
USD 1.96
(30.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 140.71 Million USD | 11.15% |
| 2021 | 126.59 Million USD | 15.74% |
| 2020 | 109.38 Million USD | -3.35% |
| 2019 | 113.18 Million USD | 7.86% |
| 2018 | 104.92 Million USD | 0.87% |
| 2017 | 104.02 Million USD | 25.97% |
| 2016 | 82.57 Million USD | 71.96% |
| 2015 | 48.02 Million USD | 83.69% |
| 2014 | 26.14 Million USD | 77.2% |
| 2013 | 14.75 Million USD | -23.18% |
| 2012 | 19.2 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 37.48 Million USD | 0.68% |
| 2023 Q1 | 37.23 Million USD | 18.7% |
| 2022 Q1 | 28.29 Million USD | 17.33% |
| 2022 FY | 140.71 Million USD | 11.15% |
| 2022 Q2 | 48.26 Million USD | 70.62% |
| 2022 Q3 | 32.78 Million USD | -32.07% |
| 2022 Q4 | 31.36 Million USD | -4.33% |
| 2021 FY | 126.59 Million USD | 15.74% |
| 2021 Q3 | 41.77 Million USD | 57.35% |
| 2021 Q4 | 24.11 Million USD | -42.28% |
| 2021 Q2 | 26.54 Million USD | -22.3% |
| 2021 Q1 | 34.16 Million USD | 23.87% |
| 2020 Q3 | 22.52 Million USD | -10.24% |
| 2020 Q1 | 34.18 Million USD | 1.22% |
| 2020 Q2 | 25.09 Million USD | -26.59% |
| 2020 Q4 | 27.58 Million USD | 22.45% |
| 2020 FY | 109.38 Million USD | -3.35% |
| 2019 Q2 | 26.18 Million USD | 6.81% |
| 2019 Q4 | 33.77 Million USD | 17.63% |
| 2019 Q3 | 28.7 Million USD | 9.64% |
| 2019 FY | 113.18 Million USD | 7.86% |
| 2019 Q1 | 24.51 Million USD | 14.91% |
| 2018 Q3 | 19.85 Million USD | -36.47% |
| 2018 Q2 | 31.25 Million USD | -3.88% |
| 2018 Q1 | 32.51 Million USD | 42.85% |
| 2018 FY | 104.92 Million USD | 0.87% |
| 2018 Q4 | 21.33 Million USD | 7.46% |
| 2017 Q4 | 22.76 Million USD | -11.17% |
| 2017 Q2 | 30.38 Million USD | 16.41% |
| 2017 Q1 | 26.1 Million USD | -23.31% |
| 2017 FY | 104.02 Million USD | 25.97% |
| 2017 Q3 | 25.62 Million USD | -15.67% |
| 2016 Q1 | 17.64 Million USD | 22.65% |
| 2016 Q4 | 34.03 Million USD | 125.4% |
| 2016 Q3 | 15.1 Million USD | -4.36% |
| 2016 Q2 | 15.78 Million USD | -10.54% |
| 2016 FY | 82.57 Million USD | 71.96% |
| 2015 Q4 | 14.39 Million USD | 16.32% |
| 2015 FY | 48.02 Million USD | 83.69% |
| 2015 Q3 | 12.37 Million USD | 12.58% |
| 2015 Q2 | 10.98 Million USD | 6.99% |
| 2015 Q1 | 10.27 Million USD | 33.81% |
| 2014 Q3 | 9.74 Million USD | 34.97% |
| 2014 FY | 26.14 Million USD | 77.2% |
| 2014 Q4 | 7.67 Million USD | -21.22% |
| 2014 Q2 | 7.21 Million USD | 37.54% |
| 2014 Q1 | 5.24 Million USD | 33.45% |
| 2013 Q2 | 890.23 Thousand USD | -83.74% |
| 2013 Q1 | 5.47 Million USD | 31.92% |
| 2013 Q3 | 4.23 Million USD | 376.25% |
| 2013 FY | 14.75 Million USD | -23.18% |
| 2013 Q4 | 3.93 Million USD | -7.24% |
| 2012 Q3 | 4.43 Million USD | 0.0% |
| 2012 Q4 | 4.14 Million USD | -6.43% |
| 2012 FY | 19.2 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -1605.031% |
| BioQuest Corp. | 89.76 USD | -156766834.046% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -564.717% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -1346.063% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | 238.36 Thousand USD | -58933.243% |
| Instadose Pharma Corp. | - USD | -Infinity% |